Valley Fever Solutions

Bringing New Hope to an Orphan Disease

Valley Fever Solutions
Ask your doctor to test you for Valley Fever

A first-in-class compound, New Mechanism of Action

News - VFS at upcoming 10th Biotech Showcase

  We are excited to join once again the Biotech Showcase, a major conference in San Francisco's busy Healthcare Week, January 8-10, 2018.
  We will be presenting Monday, January 8 at 11 am in Franciscan D.
  We are engaging a manufacturer to make large scale trial material. This is an important milestaone to set up proof of concept trials starting in early 2019.

Nikkomycin Z (NikZ) is first in a new class of antifungal
  • Novel mechanism of action, expected to raise the standard of care
  • Selective to fungal cells - thus far no safety concerns in mammals
  • May enhance other anti-fungal treatments in combination with other drugs
  • Scaled up trial material in process, Phase IIa trials in sick humans Early 2019

Valley Fever Solutions, Inc. (VFS, an Arizona corporation), is developing Nikkomycin Z (NikZ) as a dramatically superior potential cure for Valley Fever. VF is a painful and debilitating orphan disease causing annually over 2,000 serious cases, 9K hospitalizations, and 150 deaths. About 60,000 people are sickened each year, suffering for months. Victims with more serious cases suffer for years. Each year, another 1,000 patients have serious disease - with no therapeutic options, as the current drugs do not work for them.

Collectively, the market for antifungals across a spectrum of disease organisms generally simlar to cocci approaches $1B. Broadly, worldwide antifungal sales exceed $6B. NikZ for Valley Fever, our first indication, has Orphan Product designation. In 2014 we added GAIN Act QIDP designation. These provide for 7 and 5 years sequential market exclusivity after marketing approval. We expect to reach sales of $50M quickly and peak sales of $130M for Valley Fever fairly quickly with our many advantages over standard-of-care drugs. We expect therapeutic benefit in other indications in immunosuppressed patients, expecting a 2-3x revenue mutiplier.

Our Phase I results were very promising. We are pursuing patents related to the new manufacturing process for NikZ. VFS is seeking a tranched A round or a partnership to reach proof of concept in mid 2019. We could start a pivotal trial in January 2019 with support now. We anticipate an independent showing of human efficacy working with an existing trial at the NIH.

We are seeking $6M to conduct a small proof of concept trial much sooner in a small population of more typical subjects, our "sweet spot" trial. We are making progress under an NIH grant to conduct a clinical trial in patients with new infection, a trial we hope to begin in 2019. An NIH contract delivered some GMP product by an older process.

We are scaling up our pilot scale process to make a large batch of new trial material (API and drug product) in late 2018. We will begin Phase IIa patient enrollment shortly after having trial material, anticipating results 4-7 months later, and early results within the first 2 months (endpoint confirmation, some dose ranging). With investor support, the sweet spot proof of concept trial could give results as soon as May 2019. We expect to be a good candidate for an additional $2M FDA orphan product trial grant in 2019.

Valley Fever Solutions

1830 E. Broadway, #124-182
Tucson, AZ 85719
Tel: 650-454-4126
‚Äč Mail: info@ValleyFeverSolutions.com

Resources... Next Page ⟩
Speaking:
Upcoming
  • Biotech Showcase, January 8, 2018
  • Franciscan D, 11 am Monday

    Recent
  • Cocci Study Group, August 10-13, 2017
  • Seventh International Cocci conference

  • BIO, June 19-22, 2017, San Diego
  • Premiere International BIO conference



    Temple at Nikko, Japan where the organism that produces Nikkomycin-Z was discovered

    Temple at Nikko, Japan